Cargando…

Different general strategies for deprescribing in real clinical settings: From lists to collaborative care

Most elderly patients with mental disorders are treated with polypharmacy (e.g., five or more medications), and they are receiving medications that are potentially inappropriate for elderly patients (e.g., PIMs). These aspects are often excluded in the clinical guidelines, meta-analyses, and randomi...

Descripción completa

Detalles Bibliográficos
Autor principal: Stuhec, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471574/
http://dx.doi.org/10.1192/j.eurpsy.2021.182
_version_ 1784789109173125120
author Stuhec, M.
author_facet Stuhec, M.
author_sort Stuhec, M.
collection PubMed
description Most elderly patients with mental disorders are treated with polypharmacy (e.g., five or more medications), and they are receiving medications that are potentially inappropriate for elderly patients (e.g., PIMs). These aspects are often excluded in the clinical guidelines, meta-analyses, and randomized controlled trials but are very important for prudent prescribing in daily practice. The most robust approach to reducing irrational polypharmacy, PIMs, and other medications-related problems in this population is a careful deprescribing process. It is the process of tapering, withdrawing, discontinuing, or stopping medications. There are some tools available to help in the deprescribing process in clinical practice, including different medication lists (e.g., Beers criteria, STOPP/START, and guidelines) and collaborative care, including clinical pharmacist or pharmacologist. Medication lists have been used in clinical trials and guidelines, where Beers criteria are used predominantly in the U.S. and Priscus list in Europe. A collaborative care approach, including a clinical pharmacist, has been established only in some countries (e.g., USA, UK & Slovenia). The results are positive with a decrease of PIMs, polypharmacy, and an increase in the patients’ quality of life. The participants will learn the general deprescribing processes supported by the evidence-based data and real clinical pharmacological tools useful for daily practice. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9471574
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94715742022-09-29 Different general strategies for deprescribing in real clinical settings: From lists to collaborative care Stuhec, M. Eur Psychiatry Abstract Most elderly patients with mental disorders are treated with polypharmacy (e.g., five or more medications), and they are receiving medications that are potentially inappropriate for elderly patients (e.g., PIMs). These aspects are often excluded in the clinical guidelines, meta-analyses, and randomized controlled trials but are very important for prudent prescribing in daily practice. The most robust approach to reducing irrational polypharmacy, PIMs, and other medications-related problems in this population is a careful deprescribing process. It is the process of tapering, withdrawing, discontinuing, or stopping medications. There are some tools available to help in the deprescribing process in clinical practice, including different medication lists (e.g., Beers criteria, STOPP/START, and guidelines) and collaborative care, including clinical pharmacist or pharmacologist. Medication lists have been used in clinical trials and guidelines, where Beers criteria are used predominantly in the U.S. and Priscus list in Europe. A collaborative care approach, including a clinical pharmacist, has been established only in some countries (e.g., USA, UK & Slovenia). The results are positive with a decrease of PIMs, polypharmacy, and an increase in the patients’ quality of life. The participants will learn the general deprescribing processes supported by the evidence-based data and real clinical pharmacological tools useful for daily practice. DISCLOSURE: No significant relationships. Cambridge University Press 2021-08-13 /pmc/articles/PMC9471574/ http://dx.doi.org/10.1192/j.eurpsy.2021.182 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Stuhec, M.
Different general strategies for deprescribing in real clinical settings: From lists to collaborative care
title Different general strategies for deprescribing in real clinical settings: From lists to collaborative care
title_full Different general strategies for deprescribing in real clinical settings: From lists to collaborative care
title_fullStr Different general strategies for deprescribing in real clinical settings: From lists to collaborative care
title_full_unstemmed Different general strategies for deprescribing in real clinical settings: From lists to collaborative care
title_short Different general strategies for deprescribing in real clinical settings: From lists to collaborative care
title_sort different general strategies for deprescribing in real clinical settings: from lists to collaborative care
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471574/
http://dx.doi.org/10.1192/j.eurpsy.2021.182
work_keys_str_mv AT stuhecm differentgeneralstrategiesfordeprescribinginrealclinicalsettingsfromliststocollaborativecare